证券代码：300318 证券简称：博晖创新 公告编号：临 2023-052 生产单位：博晖生物制药（河北）有限公司； 法定代表人：崔卫东； 机构名称：罗平博晖单采血浆站； 主要负责人：朱弋黔； 地址：云南省曲靖市罗平县罗雄街道白龙潭综合物流园区（罗平四中对面）； 业务项目：原料血浆采集； 许可证号：云卫浆准字[2023]第 04 号； 北京博晖创新生物技术集团股份有限公司 关于控股子公司下属浆站取得单采血浆许可证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北京博晖创新生物技术集团股份有限公司（以下简称"公司"）控股子 公司博晖生物制药（河北）有限公司下属罗平博晖单采血浆有限公司（以下简称 "罗平浆站"）取得云南省卫生健康委员会颁发的《单采血浆许可证》，罗平浆站 经核准登记，准予执业。主要信息如下： 有效期限：2023 年 11 月 21 日至 2025 年 11 月 20 日。 特此公告。 北京博晖创新生物技术集团股份有限公司 董 事 会 2023 年 11 月 23 日 采浆区域：罗平县行政区域内； ...

北京博晖创新生物技术集团股份有限公司 2023 年第三季度报告 证券代码：300318 证券简称：博晖创新 公告编号：临 2023-051 北京博晖创新生物技术集团股份有限公司 2023 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度报告是否经过审计 □是 否 1 北京博晖创新生物技术集团股份有限公司 2023年第三季度报告 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增減 | | 营业收入(元) | 279.191.923.6 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2023-048 北京博晖创新生物技术集团股份有限公司 第八届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、审议通过《2023 年第三季度报告》 同意公司根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所创 业板上市公司第 47 号——上市公司季度报告公告格式》等法律、法规的相关要 求，结合本公司 2023 年第三季度的实际经营管理情况编制的《2023 年第三季度 报告》。该报告未经会计师事务所审计。 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 第八届董事会第三次会议于 2023 年 10 月 27 日在公司会议室召开，会议通知于 2023 年 10 月 17 日以专人送达、邮件通知或电话通知的方式送达各位董事，会 议由公司董事长沈治卫先生主持，会议采取现场和通讯表决相结合方式进行，本 次会议应出席董事 7 人，实际出席董事 7 人，监事和高级管理人员列席了会议。 本次会议的召集召开程序符合《公司法》和《公司章程 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2023-049 北京博晖创新生物技术集团股份有限公司 第八届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"）第 八届监事会第三次会议于 2023 年 10 月 27 日在公司会议室召开，会议通知于 2023 年 10 月 17 日以专人送达、邮件通知或电话通知的方式送达各位监事。会议由公司 监事会主席杜江虹女士主持，会议采取现场和通讯表决相结合方式进行，本次会议 应出席监事 3 人，实际出席监事 3 人。本次会议的召集召开程序符合《公司法》和 《公司章程》的有关规定。 二、监事会会议审议情况 本次会议审议通过了以下议案： 1、审议通过《2023 年第三季度报告》 监事会认为：公司结合 2023 年第三季度的实际经营管理情况编制的《2023 年 第三季度报告》符合《深圳证券交易所创业板股票上市规则》、《上市公司信息披露 管理办法》等法律、法规的相关要求。其内容真实、准确、完整的反映了公 ...

Group 1: Company Overview - The company was listed on May 23, 2012, and has two main business segments: inspection and testing services, and blood products [2] - The inspection and testing business has maintained stable revenue in recent years, while blood products have become a key area of development since entering the sector in 2015 [2] Group 2: Blood Plasma Collection - The company currently operates 15 plasma collection stations, with 6 in Yunnan, 2 in Inner Mongolia, and 1 in Shandong, among others [2] - In the first half of 2023, the company collected approximately 202 tons of plasma, with an expectation to exceed 400 tons for the entire year [2] Group 3: Production Capacity and Projects - The designed production capacity for the Yunnan blood product project is 1,500 tons of raw plasma per year, while the Inner Mongolia factory is designed for 800-1,000 tons [3] - The Yunnan project has completed construction and equipment installation, but the official operation date is pending government approval for production qualification [3] Group 4: Product Development and Market Position - The company is developing new products, including "Human Coagulation Factor VIII," which is in clinical stages, and "Human Fibrinogen," which is under research [3] - The company’s blood product revenue is currently lower than industry peers due to processing capacity constraints, with existing facilities operating at full capacity [3]

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 526.91 million, representing a 37.46% increase compared to CNY 383.31 million in the same period last year[24]. - The net profit attributable to shareholders was CNY 5.93 million, a significant turnaround from a loss of CNY 19.78 million in the previous year, marking a 129.96% increase[24]. - The net cash flow from operating activities reached CNY 80.39 million, a remarkable increase of 499.75% compared to a negative cash flow of CNY 20.11 million in the same period last year[24]. - The basic earnings per share improved to CNY 0.0073, compared to a loss of CNY 0.0242 per share in the previous year, reflecting a 130.17% increase[24]. - The total assets at the end of the reporting period were CNY 3.88 billion, a slight decrease of 0.61% from CNY 3.91 billion at the end of the previous year[24]. - The net assets attributable to shareholders increased by 0.52% to CNY 1.40 billion from CNY 1.39 billion at the end of the previous year[24]. - The weighted average return on net assets improved to 0.42%, up from -2.05% in the previous year[24]. - The company reported a net profit excluding non-recurring gains and losses of CNY 5.22 million, compared to a loss of CNY 21.26 million in the same period last year, representing a 124.57% increase[24]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2023, representing a 15% year-over-year growth[45]. - The company has outlined a positive outlook for the second half of 2023, projecting a revenue growth of 10% to 1.32 billion RMB[45]. Business Segments - The company's main business segments include inspection testing and biological products[32]. - In the reporting period, the inspection testing business generated revenue of 133.75 million yuan, a decrease of 0.3% year-on-year[37]. - Revenue from in vitro diagnostic products was 85.02 million yuan, down 1.84% compared to the previous year[37]. - Revenue from non-medical testing products increased by 2.5% to 48.73 million yuan[37]. - The company’s main medical testing products include human trace element testing and HPV testing, targeting hospitals and third-party testing institutions[38]. Product Development and Innovation - The company is focused on expanding its product line in the medical device sector, particularly in immunoassay and atomic absorption technologies[40]. - The company is investing in R&D for advanced diagnostic technologies, with a focus on quantum dot fluorescence immunoassay methods, aiming to enhance testing accuracy and efficiency[46]. - The company is developing a nucleic acid chip detection instrument (Class II) for qualitative detection of 24 types of human papillomavirus, with a registration valid until November 26, 2028[42]. - The company has a new product for detecting respiratory viruses (Class III), which is intended for qualitative detection of influenza A and B viruses, with a registration expiring on February 28, 2026[42]. - The company’s total IgE antibody testing kit is expected to be launched by July 27, 2027, utilizing quantum dot immunofluorescence technology[48]. - The company is developing a fully automated nucleic acid detection analysis system, expected to be registered by May 30, 2028, for qualitative detection of target nucleic acids[48]. Market Expansion and Strategy - Market expansion plans include entering three new international markets by the end of 2024, targeting a 25% increase in international sales[45]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 200 million RMB allocated for potential mergers and acquisitions in 2024[45]. - The company aims to increase its market share in the diagnostic sector by 5% over the next year through aggressive marketing strategies and partnerships[45]. - The company is actively pursuing market expansion, with plans to enter three new provinces by Q4 2023, aiming for a 10% market share in these regions[172]. Quality Management and Compliance - The company has not identified any significant risk factors that could adversely affect its operational, financial, or profitability status[4]. - The company emphasizes quality management, having achieved certifications for medical device GMP, ISO13485, and ISO9001, ensuring high-quality product supply[64]. - The company has established a comprehensive quality management system to mitigate potential risks related to product safety, particularly in blood products[97]. Environmental Responsibility - The company is committed to sustainability and environmental responsibility, as evidenced by its ongoing projects and compliance with environmental regulations[138]. - The company has a wastewater treatment capacity of 400 tons per day, utilizing a comprehensive treatment process including neutralization, sedimentation, A/O, MBR, and disinfection with hypochlorous acid[143]. - The company has implemented upgrades to its wastewater treatment facilities, enhancing compliance with environmental regulations[136]. - The company has established internal wastewater treatment facilities to handle industrial wastewater generated during operations[140]. - The company has a monitoring system for wastewater with various parameters, including a maximum limit of 500 mg/L for fecal coliform bacteria, monitored quarterly[157]. Shareholder and Governance Matters - The annual shareholders' meeting had a participation rate of 45.47% on June 29, 2023[105]. - No cash dividends or stock bonuses were distributed for the half-year period, and no capital reserve was converted into share capital[108]. - The company appointed new directors and management on June 29, 2023, including a new chairman and several non-independent directors[106]. - The company has maintained a clean record with no significant litigation or arbitration matters reported in the first half of 2023[179]. Financial Management - The company has no significant related party transactions during the reporting period, ensuring transparency in operations[181][183]. - The company has no significant guarantees or collateral obligations reported, maintaining a conservative financial position[195]. - The company reported a total of 30 million yuan in claims related to a lawsuit that is still in the filing stage[184]. - The company has ongoing significant contracts that may impact its financial performance[200].

北京博晖创新生物技术集团股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | | 资金占用方名称 | 占用方与上市 | 上市公司核算的 | 2023 | 年期初占用资 | 2023 年 | 1-6 月份占用 | 2023年1-6月份占用 | | 2023年1-6月份偿 | 2023 年 | 6 月期 | 占用形成原 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | 公司的关联关 | 会计科目 | | 金余额 | | 累计发生金额（不含利 | 资金的利息（如有） | | 还累计发生金额 | 末占用资金余 | | 因 | | | | | 系 | | | | | 息） | | | | 额 | | | | | 控股股东、实际控制人 | - | - | - | | - | | - | - | | - | - | | | | | 及其附属企业 | | - | - | | - | | - | - | | ...

2、公司没有为控股股东、实际控制人及其他关联方、任何非法人单位或个 人提供担保的情形；控股股东、实际控制人及其他关联方也未强制公司为他人 提供担保。截至报告期末，公司不存在任何对外担保情形。 （以下无正文） （本页无正文，为《北京博晖创新生物技术集团股份有限公司独立董事关于第八 届董事会第二次会议相关事项的独立意见》之签字页） 独立董事签名： 北京博晖创新生物技术集团股份有限公司独立董事 关于第八届董事会第二次会议相关事项的独立意见 根据《上市公司独立董事规则》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等法 律法规、规范性文件，以及《北京博晖创新生物技术集团股份有限公司章程》《北 京博晖创新生物技术集团股份有限公司独立董事工作规则》等有关规定，作为北 京博晖创新生物技术集团股份有限公司（以下简称"博晖创新"或"公司"）的独立 董事，我们基于实事求是、独立判断的立场和态度，在审阅相关议案资料后，基 于独立判断立场，本着认真负责的态度对公司第八届董事会第二次会议审议的以 下相关事项进行了认真审议并发表如下独立意见： 一、关于控股股东及其他关联方占用 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2023-046 北京博晖创新生物技术集团股份有限公司 第八届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、审议通过《2023 年半年度报告及其摘要》 经审核，监事会认为公司编制的《2023 年半年度报告》及其摘要的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的 实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票同意，0 票反对，0 票弃权。同意票数占总票数的 100%。 三、备查文件 1、第八届监事会第二次会议决议。 特此公告。 一、监事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"）第 八届监事会第二次会议于 2023 年 8 月 29 日在公司会议室召开，会议通知于 2023 年 8月 18日以专人送达、邮件通知或电话通知的方式送达各位监事。会议由公司监事 会主席杜江虹女士主持，会议采取现场和通讯表决相结合方式进行，本次会议应出 席监事 3 人，实际出席监事 3 人。本次 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2023-045 同意公司根据《深圳证券交易所创业板股票上市规则》、《公开发行证券的公 司信息披露内容与格式准则第 3 号——半年度报告的内容与格式》等法律、法规 的相关要求，结合本公司 2023 年上半年的实际经营管理情况编制的《2023 年半 年度报告》及其摘要，该报告及其摘要未经会计师事务所审计。 北京博晖创新生物技术集团股份有限公司 第八届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 第八届董事会第二次会议于 2023 年 8 月 29 日在公司会议室召开，会议通知于 2023 年 8 月 18 日以专人送达、邮件通知或电话通知的方式送达各位董事，会议 由公司董事长沈治卫先生主持，会议采取现场和通讯表决相结合方式进行，本次 会议应出席董事 7 人，实际出席董事 7 人，监事和高级管理人员列席了会议。本 次会议的召集召开程序符合《公司法》和《公司章程》的有关规定。 二、董事会 ...